title: Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia.
abstract: We investigated whether previously reported muscle mitochondrial dysfunction and altered gene transcript levels in type 2 diabetes might be secondary to abnormal blood glucose and insulin levels rather than an intrinsic defect of type 2 diabetes. A total of 13 type 2 diabetic and 17 nondiabetic subjects were studied on two separate occasions while maintaining similar insulin and glucose levels in both groups by 7-h infusions of somatostatin, low- or high-dose insulin (0.25 and 1.5 mU/kg of fat-free mass per min, respectively), and glucose. Muscle mitochondrial DNA abundance was not different between type 2 diabetic and nondiabetic subjects at both insulin levels, but the majority of transcripts in muscle that are involved mitochondrial functions were expressed at lower levels in type 2 diabetes at low levels of insulin. However, several gene transcripts that are specifically involved in the electron transport chain were expressed at higher levels in type 2 diabetic patients. After the low-dose insulin infusion, which achieved postabsorptive insulin levels, the muscle mitochondrial ATP production rate (MAPR) was not different between type 2 diabetic and nondiabetic subjects. However, increasing insulin to postprandial levels increased the MAPR in nondiabetic subjects but not in type 2 diabetic patients. The lack of MAPR increment in response to high-dose insulin in type 2 diabetic patients occurred in association with reduced glucose disposal and expression of peroxisome proliferator-activated receptor-gamma coactivator 1alpha, citrate synthase, and cytochrome c oxidase I. In conclusion, the current data supports that muscle mitochondrial dysfunction in type 2 diabetes is not an intrinsic defect, but instead a functional defect related to impaired response to insulin.
authors.affiliation: Endocrinology Research Unit, Mayo Clinic, 200 First St. SW, Joseph 5-194, Rochester, MN 55905, USA.
authors.forename: Yan W
authors.initials: YW
authors.lastname: Asmann
authors.forename: Craig S
authors.initials: CS
authors.lastname: Stump
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Short
authors.forename: Jill M
authors.initials: JM
authors.lastname: Coenen-Schimke
authors.forename: Zengkui
authors.initials: Z
authors.lastname: Guo
authors.forename: Maureen L
authors.initials: ML
authors.lastname: Bigelow
authors.forename: K Sreekumaran
authors.initials: KS
authors.lastname: Nair
mesh_terms: D001706:Biopsy; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D015992:Body Mass Index; D004272:DNA, Mitochondrial / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D020869:Gene Expression Profiling; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology; D008875:Middle Aged; D008931:Mitochondria, Muscle / Q000473:pathology / Q000502:physiology*; D018482:Muscle, Skeletal / Q000166:cytology* / Q000473:pathology; D012016:Reference Values; D014158:Transcription, Genetic
chemical_list: D001786:Blood Glucose; D004272:DNA, Mitochondrial; D007328:Insulin